1. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
- Author
-
Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, and Mencoboni M
- Subjects
- Adult, Aged, Carboplatin adverse effects, Confidence Intervals, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Glutamates adverse effects, Guanine administration & dosage, Guanine adverse effects, History, Ancient, Humans, Kaplan-Meier Estimate, Male, Maximum Tolerated Dose, Mesothelioma mortality, Middle Aged, Neoplasm Staging, Pemetrexed, Pleural Neoplasms mortality, Probability, Risk Assessment, Survival Analysis, Treatment Outcome, Carboplatin administration & dosage, Glutamates administration & dosage, Guanine analogs & derivatives, Mesothelioma drug therapy, Mesothelioma pathology, Pleural Neoplasms drug therapy, Pleural Neoplasms pathology
- Abstract
Background: The aim of this study was to evaluate the activity and toxicity of pemetrexed and carboplatin combination as first-line chemotherapy in malignant pleural mesothelioma (MPM)., Patients and Methods: Patients with measurable advanced MPM and a zero to two Eastern Cooperative Oncology Group (ECOG) performance status (PS) were enrolled. The schedule was pemetrexed 500 mg/m(2) in combination with carboplatin area under the curve 5, every 21 days. In all, 76 patients were treated. Median age was 65 years; median ECOG PS was zero., Results: Grade 3 hematological toxicity according to World Health Organization criteria was seen in 36 (47.3%) patients; grade 4 hematological toxicity in 5 (6.5%) patients. There were 16 (21%) partial responses and 3 (4%) complete responses, for an overall response rate of 19 (25%) [95% confidence interval (CI) 15.3-34.7]. In all, 29 (39%) (95% CI 28-48) patients reported stable disease. The median survival was estimated at 14 months., Conclusion: This combination of carboplatin and pemetrexed is moderately active and the toxicity is acceptable.
- Published
- 2008
- Full Text
- View/download PDF